Bulgaria - bulgarsk - БАБХ (Българска агенция по безопасност на храните)

invesa international, s.a. - Цефалексин (монохидрат); Гентамицин (сулфат) - интрамамарна суспензия - 350 mg/10 ml, 35 mg/10 ml - крави

Bulgaria - bulgarsk - БАБХ (Българска агенция по безопасност на храните)

richter pharma ag - Метамизол натрий, кофеин, Калциев глюконат, магнезиев глюконат, натриев дигидрофосфат дигидрат, acetylmethionine и/или глюкоза (като монохидрат) - инжекционен разтвор - 4.00 g/100 ml; 0,35 g/100 ml; 10.00 g/100 ml; 1.00 g/100 ml; 0, 402 g/100 ml; 4.00 g/100 ml; 18,182 g/100 ml - говеда, коне, свине, телета

Bulgaria - bulgarsk - БАБХ (Българска агенция по безопасност на храните)

merial - Бензилпенициллин ( като прокаин монохидрат); Дигидрострептомицин (като сулфат) - инжекционна суспензия - 114 mg/ml; 164 mg/ml - говеда, кози, коне, овце, свине

Bulgaria - bulgarsk - БАБХ (Българска агенция по безопасност на храните)

virbac - Цефалексина (като монохидрат) - инжекционна суспензия - 15 g/100 ml - говеда

Bulgaria - bulgarsk - БАБХ (Българска агенция по безопасност на храните)

virbac - Цефалексина (като монохидрат) - интрамамарна суспензия - 200 mg/спринцовка - крави

Den europeiske union - bulgarsk - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - Антинеопластични средства - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Den europeiske union - bulgarsk - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - Имуносупресори - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) е показан за лечение на възрастни пациенти с по-рано нелекувана множествена миеломой, на които не се разчита за трансплантация. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Den europeiske union - bulgarsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - Захарен диабет тип 2 - Лекарства, използвани при диабет - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. тройно комбинирано лечение) като допълнение към диета и упражнения при пациенти, недостатъчно контролирани за тяхното максимално переносимой дозата на метформина и сульфонилмочевины. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Den europeiske union - bulgarsk - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - Новообразувания На Простатата, Кастраци-Упорит - Антинеопластични средства - treatment of adult patients with prostate cancer.

Den europeiske union - bulgarsk - EMA (European Medicines Agency)

viiv healthcare b.v. - маравирок - ХИВ инфекции - Антивирусни средства за системно приложение - celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only ccr5-tropic hiv-1 detectable,.